24 January 2018
News and Views
Links and Services
A study in November's issue of the Alimentary Pharmacology & Therapeutics evaluates the prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidemia.
In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and presumably associ
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors